Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | EEF2K | O00418 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6430738 | 1.00 | PTGS2 (0.45) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL2745322 | 0.91 | PTGS2 (0.52) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL2746044 | 0.91 | PTGS2 (0.52) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL2746042 | 0.91 | PTGS2 (0.52) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL2745319 | 0.91 | PTGS2 (0.52) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL8991929 | 0.84 | PTGS2 (0.45) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL8894724 | 0.84 | PTGS2 (0.45) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL8933401 | 0.81 | PTGS2 (0.49) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL8895650 | 0.81 | PTGS2 (0.49) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL7700021 | 0.80 | PTGS2 (0.48) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6746678-B1 | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments | SECANT PHARMA, LLC | 2004-06-08 | — | — | US | claimed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | PTGS2 33/4885PTGS1 11/4885ALOX5 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.